Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05842044 · ClinicalTrials.gov registry record · Phase 2
NSAID Use After Robotic Partial Nephrectomy
A Phase 2 study of Kidney Cancer and Renal Cancer, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT05842044 is a Phase 2 study of Kidney Cancer and Renal Cancer that is actively recruiting participants, run by University of Miami. The registered enrollment target is 110 participants, below the 879-participant average among 60 other Kidney Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05842044, a Phase 2 study of Kidney Cancer and Renal Cancer, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see how effective non-steroidal anti-inflammatory drugs (NSAIDs) are at controlling pain without side effects in participants after robotic-assisted partial nephrectomy.
Conditions Studied
Interventions
- DRUG Acetaminophen
- DRUG Ketorolac
- DRUG Ibuprofen
- DRUG Oxycodone
- DRUG Hydromorphone
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05842044
The ClinicalTrials.gov registry entry for NCT05842044 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 879-participant average among 60 other Kidney Cancer trials with a reported enrollment target (87% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Kidney Cancer appearing as the primary indexed condition, and to 5 interventions - of which Acetaminophen is the first listed.
NCT05842044 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05842044 about?
NCT05842044 is a clinical study titled "NSAID Use After Robotic Partial Nephrectomy". The purpose of this study is to see how effective non-steroidal anti-inflammatory drugs (NSAIDs) are at controlling pain without side effects in participants after robotic-assisted partial nephrectomy.
What is the current status of trial NCT05842044?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2023-09-15. Estimated completion is 2026-09-30.
What conditions does trial NCT05842044 study?
This clinical trial studies the following conditions: Kidney Cancer, Renal Cancer, Renal Neoplasm.
What interventions are being tested in trial NCT05842044?
The interventions under investigation include: Acetaminophen (DRUG), Ketorolac (DRUG), Ibuprofen (DRUG), Oxycodone (DRUG), Hydromorphone (DRUG).
Who is sponsoring clinical trial NCT05842044?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05842044 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.